Please Wait a Moment
X

Articles

19Jul

FDA Releases ZIKV Guidance and Grifols ZIKV Assay Licensed- 1st Update

19 Jul, 2018 | Return|

This is the first update to the original CTS communication distributed on July 6th. As previously communicated, all CTS healthcare partners will remain on the Grifols ZIKV clinical trial until at least the end of October 2018, which coincides with the end of the WNV season.

Check out the Communication page for the complete details on the NAT ZIKV test update or by clicking the link: Communications

Related

Update on CTS Implementation of the Grifols Procleix Ultrio Elite Assay

In July, all 5 CTS laboratories will convert from the current Grifols Ultrio Plus NAT triplex assay ...

Read More >

CTS Portland Implements New Laboratory Information System

On April 15, 2019, the New CTS Laboratory Information System has been successfully implemented in Po...

Read More >

Reminder-Bio-Rad Geenius HIV 1/2 Implemented

CTS implement the Bio-Rad Geenius HIV 1/2 supplemental assay on Monday September 21, 2020. The newly...

Read More >

CTS to Implement Donor HLA testing on the Stratec Gemini Instrument

On April 29, 2019, CTS will begin performing Donor-Screen HLA® Class I and II testing on the Str...

Read More >

Reminder- Re-entry Webinar

Reminder - On Wednesday June 6, 2018 at 10:00AM PST, we will be hosting a webinar regarding the chan...

Read More >

VP, Scientific Affairs Dr. Marion Lanteri Speaks at Symposium on Alternatives to Donation Deferral

As an organization dedicated to the safety of the world’s blood and plasma supply, Creative Testing...

Read More >